nach oben

Inflammation Research

Erschienen in:

29.10.2022 | Review

Role of miR-155 in inflammatory autoimmune diseases: a comprehensive review

verfasst von: Wang-Dong Xu, Si-Yu Feng, An-Fang Huang

Erschienen in: Inflammation Research | Ausgabe 12/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

MiR-155 is a member of the microRNAs (miRNAs) family and regulates gene expression post-transcriptionally by binding to the 3'UTR of target mRNA. MiR-155 has a critical role in both innate and adaptive immunity. MiR-155 is aberrantly expressed in inflammatory autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, type 1 diabetes, Sjögren's syndrome, systemic sclerosis, and inflammatory bowel disease. Functional studies suggest that miR-155 is involved in development of these diseases. In vitro and in vivo experiments have shown that inhibition of miR-155 can alter disease progression or ameliorate disease symptoms.

Materials and methods

A systematic review of relevant literatures published between January 1, 2005, and March 1, 2022 about miR-155 and its role in immune cells, autoimmune diseases was searched on PubMed, EMBASE, Google Scholar.

Conclusion

In this review, we comprehensively discussed the effects of miR-155, including role of miR-155 in different downstream signaling, which then differently regulate immune cells expression and functions. Furthermore, miR-155-mediated dysfunction of immune cells contributed to development of inflammatory autoimmune diseases. Therefore, miR-155 is expected to be a therapeutic target for inflammatory autoimmune diseases.

Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451–65. https://doi.org/10.1002/jcp.27486.CrossRefPubMed

Mahesh G, Biswas R. MicroRNA-155: a master regulator of inflammation. J Interferon Cytokine Res. 2019;39(6):321–30. https://doi.org/10.1089/jir.2018.0155.CrossRefPubMedPubMedCentral

Mashima R. Physiological roles of miR-155. Immunology. 2015;145(3):323–33. https://doi.org/10.1111/imm.12468.CrossRefPubMedPubMedCentral

Matsuyama H, Suzuki HI. Systems and synthetic microRNA biology: from biogenesis to disease pathogenesis. Int J Mol Sci. 2019;21(1):132. https://doi.org/10.3390/ijms21010132.CrossRefPubMedCentral

Vigorito E, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S, Das PP, Miska EA, Rodriguez A, Bradley A, Smith KG, Rada C, Enright AJ, Toellner KM, Maclennan IC, Turner M. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity. 2007;27(6):847–59. https://doi.org/10.1016/j.immuni.2007.10.009.CrossRefPubMedPubMedCentral

O’Connell RM, Chaudhuri AA, Rao DS, Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci U S A. 2009;106(17):7113–8. https://doi.org/10.1073/pnas.0902636106.CrossRefPubMedPubMedCentral

Teng G, Hakimpour P, Landgraf P, Rice A, Tuschl T, Casellas R, Papavasiliou FN. MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity. 2008;28(5):621–9. https://doi.org/10.1016/j.immuni.2008.03.015.CrossRefPubMedPubMedCentral

Paoletti A, Rohmer J, Ly B, Pascaud J, Rivière E, Seror R, Le Goff B, Nocturne G, Mariette X. Monocyte/macrophage abnormalities specific to rheumatoid arthritis are linked to miR-155 and are differentially modulated by different TNF inhibitors. J Immunol. 2019;203(7):1766–75. https://doi.org/10.4049/jimmunol.1900386.CrossRefPubMedPubMedCentral

Huang J, Jiao J, Xu W, Zhao H, Zhang C, Shi Y, Xiao Z. MiR-155 is upregulated in patients with active tuberculosis and inhibits apoptosis of monocytes by targeting FOXO3. Mol Med Rep. 2015;12(5):7102–8. https://doi.org/10.3892/mmr.2015.4250.CrossRefPubMed

10.

Cui B, Liu W, Wang X, Chen Y, Du Q, Zhao X, Zhang H, Liu SL, Tong D, Huang Y. Brucella Omp25 upregulates miR-155, miR-21-5p, and miR-23b to inhibit interleukin-12 production via modulation of programmed death-1 signaling in human monocyte/macrophages. Front Immunol. 2017;8:708. https://doi.org/10.3389/fimmu.2017.00708.CrossRefPubMedPubMedCentral

11.

Srinoun K, Nopparatana C, Wongchanchailert M, Fucharoen S. MiR-155 enhances phagocytic activity of β-thalassemia/HbE monocytes via targeting of BACH1. Int J Hematol. 2017;106(5):638–47. https://doi.org/10.1007/s12185-017-2291-4.CrossRefPubMed

12.

Zhou Y, Zhang P, Zheng X, Ye C, Li M, Bian P, Fan C, Zhang Y. miR-155 regulates pro- and anti-inflammatory cytokine expression in human monocytes during chronic hepatitis C virus infection. Ann Transl Med 2021;9(21):1618. https://doi.org/10.21037/atm-21-2620.

13.

Elmesmari A, Fraser AR, Wood C, Gilchrist D, Vaughan D, Stewart L, McSharry C, McInnes IB, Kurowska-Stolarska M. MicroRNA-155 regulates monocyte chemokine and chemokine receptor expression in Rheumatoid Arthritis. Rheumatology (Oxford). 2016;55(11):2056–65. https://doi.org/10.1093/rheumatology/kew272.CrossRef

14.

Billeter AT, Hellmann J, Roberts H, Druen D, Gardner SA, Sarojini H, Galandiuk S, Chien S, Bhatnagar A, Spite M, Polk HC Jr. MicroRNA-155 potentiates the inflammatory response in hypothermia by suppressing IL-10 production. FASEB J. 2014;28(12):5322–36. https://doi.org/10.1096/fj.14-258335.CrossRefPubMedPubMedCentral

15.

Janga H, Aznaourova M, Boldt F, Damm K, Grünweller A, Schulte LN. Cas9-mediated excision of proximal DNaseI/H3K4me3 signatures confers robust silencing of microRNA and long non-coding RNA genes. PLoS One. 2018;13(2): e0193066. https://doi.org/10.1371/journal.pone.0193066.CrossRefPubMedPubMedCentral

16.

Li J, Liu Y, Cao Y, Wang J, Zhao X, Jiao J, Li J, Zhang K, Yin G. Inhibition of miR-155 attenuates CD14+ monocyte-mediated inflammatory response and oxidative stress in psoriasis through TLR4/MyD88/NF-κB signaling pathway. Clin Cosmet Investig Dermatol. 2022;15:193–201. https://doi.org/10.2147/CCID.S350711.CrossRefPubMedPubMedCentral

17.

Butovsky O, Jedrychowski MP, Cialic R, Krasemann S, Murugaiyan G, Fanek Z, Greco DJ, Wu PM, Doykan CE, Kiner O, Lawson RJ, Frosch MP, Pochet N, Fatimy RE, Krichevsky AM, Gygi SP, Lassmann H, Berry J, Cudkowicz ME, Weiner HL. Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann Neurol. 2015;77(1):75–99. https://doi.org/10.1002/ana.24304.CrossRefPubMed

18.

Zhang Z, Liang K, Zou G, Chen X, Shi S, Wang G, Zhang K, Li K, Zhai S. Inhibition of miR-155 attenuates abdominal aortic aneurysm in mice by regulating macrophage-mediated inflammation. 2018. Biosci Rep. https://doi.org/10.1042/BSR20171432.

19.

Yin R, Zhu X, Wang J, Yang S, Ma A, Xiao Q, Song J, Pan X. MicroRNA-155 promotes the ox-LDL-induced activation of NLRP3 inflammasomes via the ERK1/2 pathway in THP-1 macrophages and aggravates atherosclerosis in ApoE-/- mice. Ann Palliat Med. 2019;8(5):676–689. https://doi.org/10.21037/apm.2019.10.11.

20.

Ruan Z, Chu T, Wu L, Zhang M, Zheng M, Zhang Q, Zhou M, Zhu G. miR-155 inhibits oxidized low-density lipoprotein-induced apoptosis in different cell models by targeting the p85α/AKT pathway. J Physiol Biochem. 2020;76(2):329–43. https://doi.org/10.1007/s13105-020-00738-0.CrossRefPubMed

21.

Ma YL, Ma ZJ, Wang M, Liao MY, Yao R, Liao YH. MicroRNA-155 induces differentiation of RAW264.7 cells into dendritic-like cells. Int J Clin Exp Pathol. 2015;8(11):14050–62.PubMedPubMedCentral

22.

Feng Z, Zhang X, Li L, Wang C, Feng M, Zhao K, Zhao R, Liu J, Fang Y. Tumor-associated macrophage-derived exosomal microRNA-155-5p stimulates intracranial aneurysm formation and macrophage infiltration. Clin Sci (Lond). 2019;133(22):2265–82. https://doi.org/10.1042/CS20190680.CrossRef

23.

Li X, Wang S, Mu W, Barry J, Han A, Carpenter RL, Jiang BH, Peiper SC, Mahoney MG, Aplin AE, Ren H, He J. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway. J Exp Clin Cancer Res. 2022;41(1):41. https://doi.org/10.1186/s13046-022-02244-1.CrossRefPubMedPubMedCentral

24.

Essandoh K, Li Y, Huo J, Fan GC. MiRNA-mediated macrophage polarization and its potential role in the regulation of inflammatory response. Shock. 2016;46(2):122–31. https://doi.org/10.1097/SHK.0000000000000604.PMID:26954942;PMCID:PMC4949115.CrossRefPubMedPubMedCentral

25.

Bala S, Csak T, Saha B, Zatsiorsky J, Kodys K, Catalano D, Satishchandran A, Szabo G. The pro-inflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis. J Hepatol. 2016;64(6):1378–87. https://doi.org/10.1016/j.jhep.2016.01.035.CrossRefPubMedPubMedCentral

26.

Jablonski KA, Gaudet AD, Amici SA, Popovich PG, Guerau-de-Arellano M. Control of the inflammatory macrophage transcriptional signature by miR-155. PLoS ONE. 2016;11(7): e0159724. https://doi.org/10.1371/journal.pone.0159724.CrossRefPubMedPubMedCentral

27.

Fitzsimons S, Oggero S, Bruen R, McCarthy C, Strowitzki MJ, Mahon NG, Ryan N, Brennan EP, Barry M, Perretti M, Belton O. microRNA-155 is decreased during atherosclerosis regression and is increased in urinary extracellular vesicles during atherosclerosis progression. Front Immunol. 2020;11: 576516. https://doi.org/10.3389/fimmu.2020.576516.CrossRefPubMedPubMedCentral

28.

Yang Y, Wu BQ, Wang YH, Shi YF, Luo JM, Ba JH, Liu H, Zhang TT. Regulatory effects of miR-155 and miR-146a on repolarization and inflammatory cytokine secretion in human alveolar macrophages in vitro. Immunopharmacol Immunotoxicol. 2016;38(6):502–9. https://doi.org/10.1080/08923973.2016.1248845.CrossRefPubMed

29.

Jiang K, Yang J, Guo S, Zhao G, Wu H, Deng G. Peripheral circulating exosome-mediated delivery of miR-155 as a novel mechanism for acute lung inflammation. Mol Ther. 2019;27(10):1758–71. https://doi.org/10.1016/j.ymthe.2019.07.003.CrossRefPubMedPubMedCentral

30.

Yang L, Liu L, Ying H, Yu Y, Zhang D, Deng H, Zhang H, Chai J. Acute downregulation of miR-155 leads to a reduced collagen synthesis through attenuating macrophages inflammatory factor secretion by targeting SHIP1. J Mol Histol. 2018;49(2):165–74. https://doi.org/10.1007/s10735-018-9756-5.CrossRefPubMed

31.

Li M, Cui J, Niu W, Huang J, Feng T, Sun B, Yao H. Long non-coding PCED1B-AS1 regulates macrophage apoptosis and autophagy by sponging miR-155 in active tuberculosis. Biochem Biophys Res Commun. 2019;509(3):803–9. https://doi.org/10.1016/j.bbrc.2019.01.005.CrossRefPubMed

32.

Chen L, Hu L, Zhu X, Wang Y, Li Q, Ma J, Li H. MALAT1 overexpression attenuates AS by inhibiting ox-LDL-stimulated dendritic cell maturation via miR-155-5p/NFIA axis. Cell Cycle. 2020;19:2472–85. https://doi.org/10.1080/15384101.2020.1807094.CrossRefPubMedPubMedCentral

33.

Hodge J, Wang F, Wang J, Liu Q, Saaoud F, Wang Y, Singh UP, Chen H, Luo M, Ai W, Fan D. Overexpression of microRNA-155 enhances the efficacy of dendritic cell vaccine against breast cancer. Oncoimmunology. 2020;9(1):1724761. https://doi.org/10.1080/2162402X.2020.1724761.CrossRefPubMedPubMedCentral

34.

Wang J, Iwanowycz S, Yu F, Jia X, Leng S, Wang Y, Li W, Huang S, Ai W, Fan D. microRNA-155 deficiency impairs dendritic cell function in breast cancer. Oncoimmunology. 2016;5(11): e1232223. https://doi.org/10.1080/2162402X.2016.1232223.CrossRefPubMedPubMedCentral

35.

Martinez-Nunez RT, Louafi F, Friedmann PS, Sanchez-Elsner T. MicroRNA-155 modulates the pathogen binding ability of dendritic cells (DCs) by down-regulation of DC-specific intercellular adhesion molecule-3 grabbing non-integrin (DC-SIGN). J Biol Chem. 2009;284(24):16334–42. https://doi.org/10.1074/jbc.M109.011601.CrossRefPubMedPubMedCentral

36.

Gao Y, Liu F, Zhou Q, Guo M, Zhang M, Guo W, Wang L, Hu L, Hu C, Shi Y, Liu Y, Wang Q. mir-155 regulates cardiac allograft rejection by targing the expression of suppressor of cytokine signaling-1 (DOCS1) in dendritic cells. Int J Clin Exp Med. 2014;7(11):4572–83.PubMedPubMedCentral

37.

Kravtsova-Ivantsiv Y, Shomer I, Cohen-Kaplan V, Snijder B, Superti-Furga G, Gonen H, Sommer T, Ziv T, Admon A, Naroditsky I, Jbara M, Brik A, Pikarsky E, Kwon YT, Doweck I, Ciechanover A. KPC1-mediated ubiquitination and proteasomal processing of NF-κB1 p105 to p50 restricts tumor growth. Cell. 2015;161(2):333–47. https://doi.org/10.1016/j.cell.2015.03.001.CrossRefPubMed

38.

Lu C, Huang X, Zhang X, Roensch K, Cao Q, Nakayama KI, Blazar BR, Zeng Y, Zhou X. miR-221 and miR-155 regulate human dendritic cell development, apoptosis, and IL-12 production through targeting of p27kip1, KPC1, and SOCS-1. Blood. 2011;117(16):4293–303. https://doi.org/10.1182/blood-2010-12-322503.CrossRefPubMedPubMedCentral

39.

Chen S, Smith BA, Iype J, Prestipino A, Pfeifer D, Grundmann S, Schmitt-Graeff A, Idzko M, Beck Y, Prinz G, Finke J, Duyster J, Zeiser R. MicroRNA-155-deficient dendritic cells cause less severe GVHD through reduced migration and defective inflammasome activation. Blood. 2015;126(1):103–12. https://doi.org/10.1182/blood-2014-12-617258.CrossRefPubMed

40.

Zech A, Ayata CK, Pankratz F, Meyer A, Baudiß K, Cicko S, Yegutkin GG, Grundmann S, Idzko M. MicroRNA-155 modulates P2R signaling and Th2 priming of dendritic cells during allergic airway inflammation in mice. Allergy. 2015;70(9):1121–9. https://doi.org/10.1111/all.12643.CrossRefPubMed

41.

Jia J, Li X, Guo S, Xie X. MicroRNA-155 suppresses the translation of p38 and impairs the functioning of dendritic cells in endometrial cancer mice. Cancer Manag Res. 2020;12:2993–3002. https://doi.org/10.2147/CMAR.S240926.CrossRefPubMedPubMedCentral

42.

Taghikhani A, Hassan ZM, Ebrahimi M, Moazzeni SM. microRNA modified tumor-derived exosomes as novel tools for maturation of dendritic cells. J Cell Physiol. 2019;234(6):9417–27. https://doi.org/10.1002/jcp.27626.CrossRefPubMed

43.

Jin C, Cheng L, Höxtermann S, Xie T, Lu X, Wu H, Skaletz-Rorowski A, Brockmeyer NH, Wu N. MicroRNA-155 is a biomarker of T-cell activation and immune dysfunction in HIV-1-infected patients. HIV Med. 2017;18(5):354–62. https://doi.org/10.1111/hiv.12470.CrossRefPubMed

44.

Rouquette-Jazdanian AK, Kortum RL, Li W, Merrill RK, Nguyen PH, Samelson LE, Sommers CL. miR-155 controls lymphoproliferation in LAT mutant mice by restraining T-cell apoptosis via SHIP-1/mTOR and PAK1/FOXO3/BIM pathways. PLoS One. 2015;10(6): e0131823. https://doi.org/10.1371/journal.pone.0131823.CrossRefPubMedPubMedCentral

45.

Wang X, Zhang R, Huang Z, Zang S, Wu Q, Xia L. Inhibition of the miR-155 and protein prenylation feedback loop alleviated acute graft-versus-host disease through regulating the balance between T helper 17 and Treg cells. Transpl Immunol. 2021;69: 101461. https://doi.org/10.1016/j.trim.2021.101461.CrossRefPubMed

46.

Zhang Y, Sun E, Li X, Zhang M, Tang Z, He L, Lv K. miR-155 contributes to Df1-induced asthma by increasing the proliferative response of Th cells via CTLA-4 downregulation. Cell Immunol. 2017;314:1–9. https://doi.org/10.1016/j.cellimm.2017.01.005.CrossRefPubMed

47.

Dickey LL, Worne CL, Glover JL, Lane TE, O’Connell RM. MicroRNA-155 enhances T cell trafficking and antiviral effector function in a model of coronavirus-induced neurologic disease. J Neuroinflammation. 2016;13(1):240. https://doi.org/10.1186/s12974-016-0699-z.CrossRefPubMedPubMedCentral

48.

Shirani K, Riahi Zanjani B, Mehri S, Razavi-Azarkhiavi K, Badiee A, Hayes AW, Giesy JP, Karimi G. miR-155 influences cell-mediated immunity in Balb/c mice treated with aflatoxin M1. Drug Chem Toxicol. 2021;44(1):39–46. https://doi.org/10.1080/01480545.2018.1556682.CrossRefPubMed

49.

Singh UP, Murphy AE, Enos RT, Shamran HA, Singh NP, Guan H, Hegde VL, Fan D, Price RL, Taub DD, Mishra MK, Nagarkatti M, Nagarkatti PS. miR-155 deficiency protects mice from experimental colitis by reducing T helper type 1/type 17 responses. Immunology. 2014;143(3):478–89. https://doi.org/10.1111/imm.12328.CrossRefPubMedPubMedCentral

50.

Jevtić B, Timotijević G, Stanisavljević S, Momčilović M, Mostarica Stojković M, Miljković D. Micro RNA-155 participates in re-activation of encephalitogenic T cells. Biomed Pharmacother. 2015;74:206–10. https://doi.org/10.1016/j.biopha.2015.08.011.CrossRefPubMed

51.

Zitzer NC, Snyder K, Meng X, Taylor PA, Efebera YA, Devine SM, Blazar BR, Garzon R, Ranganathan P. MicroRNA-155 modulates acute graft-versus-host disease by impacting T cell expansion, migration, and effector function. J Immunol. 2018;200(12):4170–9. https://doi.org/10.4049/jimmunol.1701465.CrossRefPubMed

52.

Chen Y, Li L, Lu Y, Su Q, Sun Y, Liu Y, Yang D. Upregulation of miR-155 in CD4(+) T cells promoted Th1 bias in patients with unstable angina. J Cell Physiol. 2015;230(10):2498–509. https://doi.org/10.1002/jcp.24987.CrossRefPubMed

53.

Liang Z, Tang F. The potency of lncRNA MALAT1/miR-155/CTLA4 axis in altering Th1/Th2 balance of asthma. 2020. Biosci Rep. https://doi.org/10.1042/BSR20190397.

54.

Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, van Dongen S, Grocock RJ, Das PP, Miska EA, Vetrie D, Okkenhaug K, Enright AJ, Dougan G, Turner M, Bradley A. Requirement of bic/microRNA-155 for normal immune function. Science. 2007;316(5824):608–11. https://doi.org/10.1126/science.1139253.CrossRefPubMedPubMedCentral

55.

Daniel E, Roff A, Hsu MH, Panganiban R, Lambert K, Ishmael F. Effects of allergic stimulation and glucocorticoids on miR-155 in CD4+ T-cells. Am J Clin Exp Immunol. 20180;7(4):57–66.

56.

Malmhäll C, Alawieh S, Lu Y, Sjöstrand M, Bossios A, Eldh M, Rådinger M. MicroRNA-155 is essential for T(H)2-mediated allergen-induced eosinophilic inflammation in the lung. J Allergy Clin Immunol. 2014;133(5):1429–38, 1438.e1–7. https://doi.org/10.1016/j.jaci.2013.11.008.

57.

Zhu F, Li H, Liu Y, Tan C, Liu X, Fan H, Wu H, Dong Y, Yu T, Chu S, He H, Zhu X. miR-155 antagomir protect against DSS-induced colitis in mice through regulating Th17/Treg cell balance by Jarid2/Wnt/β-catenin. Biomed Pharmacother. 2020;126: 109909. https://doi.org/10.1016/j.biopha.2020.109909.CrossRefPubMed

58.

Qiu L, Zhang Y, Do DC, Ke X, Zhang S, Lambert K, Kumar S, Hu C, Zhou Y, Ishmael FT, Gao P. miR-155 modulates cockroach allergen- and oxidative stress-induced cyclooxygenase-2 in asthma. J Immunol. 2018;201(3):916–29. https://doi.org/10.4049/jimmunol.1701167.CrossRefPubMed

59.

Hou J, Hu X, Chen B, Chen X, Zhao L, Chen Z, Liu F, Liu Z. miR-155 targets Est-1 and induces ulcerative colitis via the IL-23/17/6-mediated Th17 pathway. Pathol Res Pract. 2017;213(10):1289–95. https://doi.org/10.1016/j.prp.2017.08.001.CrossRefPubMed

60.

Liu Y, Dong Y, Zhu X, Fan H, Xu M, Chen Q, Nan Z, Wu H, Deng S, Liu X, Zuo D, Yang J. MiR-155 inhibition ameliorates 2, 4, 6-Trinitrobenzenesulfonic acid (TNBS)-induced experimental colitis in rat via influencing the differentiation of Th17 cells by Jarid2. Int Immunopharmacol. 2018;64:401–10. https://doi.org/10.1016/j.intimp.2018.09.007.CrossRefPubMed

61.

Yao R, Ma YL, Liang W, Li HH, Ma ZJ, Yu X, Liao YH. MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1. PLoS ONE. 2012;7(10): e46082. https://doi.org/10.1371/journal.pone.0046082.CrossRefPubMedPubMedCentral

62.

Xu M, Zuo D, Liu X, Fan H, Chen Q, Deng S, Shou Z, Tang Q, Yang J, Nan Z, Wu H, Dong Y, Liu Y. MiR-155 contributes to Th17 cells differentiation in dextran sulfate sodium (DSS)-induced colitis mice via Jarid2. Biochem Biophys Res Commun. 2017;488(1):6–14. https://doi.org/10.1016/j.bbrc.2017.04.143.CrossRefPubMed

63.

Hu R, Huffaker TB, Kagele DA, Runtsch MC, Bake E, Chaudhuri AA, Round JL, O’Connell RM. MicroRNA-155 confers encephalogenic potential to Th17 cells by promoting effector gene expression. J Immunol. 2013;190(12):5972–80. https://doi.org/10.4049/jimmunol.1300351.CrossRefPubMed

64.

Mycko MP, Cichalewska M, Cwiklinska H, Selmaj KW. miR-155-3p drives the development of autoimmune demyelination by regulation of heat shock protein 40. J Neurosci. 2015;35(50):16504–15. https://doi.org/10.1523/JNEUROSCI.2830-15.2015.CrossRefPubMedPubMedCentral

65.

Dong J, Warner LM, Lin LL, Chen MC, O’Connell RM, Lu LF. miR-155 promotes T reg cell development by safeguarding medullary thymic epithelial cell maturation. J Exp Med. 2021;218(2): e20192423. https://doi.org/10.1084/jem.20192423.CrossRefPubMed

66.

Heyn J, Luchting B, Hinske LC, Hübner M, Azad SC, Kreth S. miR-124a and miR-155 enhance differentiation of regulatory T cells in patients with neuropathic pain. J Neuroinflammation. 2016;13(1):248. https://doi.org/10.1186/s12974-016-0712-6.CrossRefPubMedPubMedCentral

67.

Lv M, Li Z, Liu J, Lin F, Zhang Q, Li Z, Wang Y, Wang K, Xu Y. MicroRNA-155 inhibits the proliferation of CD8+ T cells via upregulating regulatory T cells in vitiligo. Mol Med Rep. 2019;20(4):3617–24. https://doi.org/10.3892/mmr.2019.10607.CrossRefPubMedPubMedCentral

68.

Liu J, Shi K, Chen M, Xu L, Hong J, Hu B, Yang X, Sun R. Elevated miR-155 expression induces immunosuppression via CD39(+) regulatory T-cells in sepsis patient. Int J Infect Dis. 2015;40:135–41. https://doi.org/10.1016/j.ijid.2015.09.016.CrossRefPubMed

69.

Wang J, Li K, Zhang X, Li G, Liu T, Wu X, Brown SL, Zhou L, Mi QS. MicroRNA-155 controls iNKT cell development and lineage differentiation by coordinating multiple regulating pathways. Front Cell Dev Biol. 2021;8: 619220. https://doi.org/10.3389/fcell.2020.619220.CrossRefPubMedPubMedCentral

70.

Burocchi A, Pittoni P, Tili E, Rigoni A, Costinean S, Croce CM, Colombo MP. Regulated expression of miR-155 is required for iNKT cell development. Front Immunol. 2015;6:140. https://doi.org/10.3389/fimmu.2015.00140.CrossRefPubMedPubMedCentral

71.

Hu R, Kagele DA, Huffaker TB, Runtsch MC, Alexander M, Liu J, Bake E, Su W, Williams MA, Rao DS, Möller T, Garden GA, Round JL, O’Connell RM. miR-155 promotes T follicular helper cell accumulation during chronic, low-grade inflammation. Immunity. 2014;41(4):605–19. https://doi.org/10.1016/j.immuni.2014.09.015.CrossRefPubMedPubMedCentral

72.

Liu WH, Kang SG, Huang Z, Wu CJ, Jin HY, Maine CJ, Liu Y, Shepherd J, Sabouri-Ghomi M, Gonzalez-Martin A, Xu S, Hoffmann A, Zheng Y, Lu LF, Xiao N, Fu G, Xiao C. A miR-155-Peli1-c-Rel pathway controls the generation and function of T follicular helper cells. J Exp Med. 2016;213(9):1901–19. https://doi.org/10.1084/jem.20160204.CrossRefPubMedPubMedCentral

73.

Ji Y, Wrzesinski C, Yu Z, Hu J, Gautam S, Hawk NV, Telford WG, Palmer DC, Franco Z, Sukumar M, Roychoudhuri R, Clever D, Klebanoff CA, Surh CD, Waldmann TA, Restifo NP, Gattinoni L. miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines. Proc Natl Acad Sci U S A. 2015;112(2):476–81. https://doi.org/10.1073/pnas.1422916112.CrossRefPubMed

74.

Jin C, Cheng L, Lu X, Xie T, Wu H, Wu N. Elevated expression of miR-155 is associated with the differentiation of CD8+ T cells in patients with HIV-1. Mol Med Rep. 2017;16(2):1584–9. https://doi.org/10.3892/mmr.2017.6755.CrossRefPubMed

75.

Gracias DT, Stelekati E, Hope JL, Boesteanu AC, Doering TA, Norton J, Mueller YM, Fraietta JA, Wherry EJ, Turner M, Katsikis PD. The microRNA miR-155 controls CD8(+) T cell responses by regulating interferon signaling. Nat Immunol. 2013;14(6):593–602. https://doi.org/10.1038/ni.2576.CrossRefPubMedPubMedCentral

76.

Qiu C, Ma J, Wang ML, Zhang Q, Li YB. MicroRNA-155 deficiency in CD8+ T cells inhibits its anti-glioma immunity by regulating FoxO3a. Eur Rev Med Pharmacol Sci. 2019;23(6):2486–2496. https://doi.org/10.26355/eurrev_201903_17396.

77.

Ji Y, Fioravanti J, Zhu W, Wang H, Wu T, Hu J, Lacey NE, Gautam S, Le Gall JB, Yang X, Hocker JD, Escobar TM, He S, Dell’Orso S, Hawk NV, Kapoor V, Telford WG, Di Croce L, Muljo SA, Zhang Y, Sartorelli V, Gattinoni L. miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8+ T cell fate. Nat Commun. 2019;10(1):2157. https://doi.org/10.1038/s41467-019-09882-8.CrossRefPubMedPubMedCentral

78.

Farroni C, Marasco E, Marcellini V, Giorda E, Valentini D, Petrini S, D’Oria V, Pezzullo M, Cascioli S, Scarsella M, Ugazio AG, De Vincentiis GC, Grimsholm O, Carsetti R. Dysregulated miR-155 and miR-125b are related to impaired B-cell responses in Down syndrome. Front Immunol. 2018;9:2683. https://doi.org/10.3389/fimmu.2018.02683.CrossRefPubMedPubMedCentral

79.

Sun W, Zhang L, Lin L, Wang W, Ge Y, Liu Y, Yang B, Hou J, Cheng X, Chen X, Wang Z. Chronic psychological stress impairs germinal center response by repressing miR-155. Brain Behav Immun. 2019;76:48–60. https://doi.org/10.1016/j.bbi.2018.11.002.CrossRefPubMed

80.

Zheng Y, Ge W, Ma Y, Xie G, Wang W, Han L, Bian B, Li L, Shen L. miR-155 regulates IL-10-producing CD24hiCD27+ B cells and impairs their function in patients with Crohn’s disease. Front Immunol. 2017;8:914. https://doi.org/10.3389/fimmu.2017.00914.CrossRefPubMedPubMedCentral

81.

Basso K, Schneider C, Shen Q, Holmes AB, Setty M, Leslie C, Dalla-Favera R. BCL6 positively regulates AID and germinal center gene expression via repression of miR-155. J Exp Med. 2012;209(13):2455–65. https://doi.org/10.1084/jem.20121387.CrossRefPubMedPubMedCentral

82.

Zhu FQ, Zeng L, Tang N, Tang YP, Zhou BP, Li FF, Wu WG, Zeng XB, Peng SS. MicroRNA-155 downregulation promotes cell cycle arrest and apoptosis in diffuse large B-cell lymphoma. Oncol Res. 2016;24(6):415–27. https://doi.org/10.3727/096504016X14685034103473.CrossRefPubMedPubMedCentral

83.

Bouamar H, Jiang D, Wang L, Lin AP, Ortega M, Aguiar RC. MicroRNA 155 control of p53 activity is context dependent and mediated by Aicda and Socs1. Mol Cell Biol. 2015;35(8):1329–40. https://doi.org/10.1128/MCB.01446-14.CrossRefPubMedPubMedCentral

84.

Dahlke C, Maul K, Christalla T, Walz N, Schult P, Stocking C, Grundhoff A. A microRNA encoded by Kaposi sarcoma-associated herpesvirus promotes B-cell expansion in vivo. PLoS ONE. 2012;7(11): e49435. https://doi.org/10.1371/journal.pone.0049435.CrossRefPubMedPubMedCentral

85.

Shen T, Sanchez HN, Zan H, Casali P. Genome-wide analysis reveals selective modulation of microRNAs and mRNAs by histone deacetylase inhibitor in B cells induced to undergo class-switch DNA recombination and plasma cell differentiation. Front Immunol. 2015;6:627. https://doi.org/10.3389/fimmu.2015.00627.CrossRefPubMedPubMedCentral

86.

Wood CD, Carvell T, Gunnell A, Ojeniyi OO, Osborne C, West MJ. Enhancer control of MicroRNA miR-155 expression in Epstein-Barr virus-infected B cells. J Virol. 2018;92(19):e00716-e718. https://doi.org/10.1128/JVI.00716-18.CrossRefPubMedPubMedCentral

87.

Chen JQ, Papp G, Póliska S, Szabó K, Tarr T, Bálint BL, Szodoray P, Zeher M. MicroRNA expression profiles identify disease-specific alterations in systemic lupus erythematosus and primary Sjögren’s syndrome. PLoS ONE. 2017;12(3): e0174585. https://doi.org/10.1371/journal.pone.0174585.CrossRefPubMedPubMedCentral

88.

Lashine YA, Salah S, Aboelenein HR, Abdelaziz AI. Correcting the expression of miRNA-155 represses PP2Ac and enhances the release of IL-2 in PBMCs of juvenile SLE patients. Lupus. 2015;24(3):240–7. https://doi.org/10.1177/0961203314552117.CrossRefPubMed

89.

Pérez-Sánchez C, Aguirre MA, Ruiz-Limón P, Barbarroja N, Jiménez-Gómez Y, de la Rosa IA, Rodriguez-Ariza A, Collantes-Estévez E, Segui P, Velasco F, Cuadrado MJ, Teruel R, González-Conejero R, Martínez C, López-Pedrera Ch. Atherothrombosis-associated microRNAs in Antiphospholipid syndrome and Systemic Lupus Erythematosus patients. Sci Rep. 2016;6:31375. https://doi.org/10.1038/srep31375.CrossRefPubMedPubMedCentral

90.

Li W, Liu S, Chen Y, Weng R, Zhang K, He X, He C. Circulating Exosomal microRNAs as Biomarkers of Systemic Lupus Erythematosus. Clinics (Sao Paulo). 2020;75: e1528. https://doi.org/10.6061/clinics/2020/e1528.CrossRef

91.

Rasmussen TK, Andersen T, Bak RO, Yiu G, Sørensen CM, Stengaard-Pedersen K, Mikkelsen JG, Utz PJ, Holm CK, Deleuran B. Overexpression of microRNA-155 increases IL-21 mediated STAT3 signaling and IL-21 production in systemic lupus erythematosus. Arthritis Res Ther. 2015;17(1):154. https://doi.org/10.1186/s13075-015-0660-z.CrossRefPubMedPubMedCentral

92.

Zununi Vahed S, Nakhjavani M, Etemadi J, Jamshidi H, Jadidian N, Pourlak T, Abediazar S. Altered levels of immune-regulatory microRNAs in plasma samples of patients with lupus nephritis. Bioimpacts. 2018;8(3):177–183. https://doi.org/10.15171/bi.2018.20.

93.

Wang G, Tam LS, Kwan BC, Li EK, Chow KM, Luk CC, Li PK, Szeto CC. Expression of miR-146a and miR-155 in the urinary sediment of systemic lupus erythematosus. Clin Rheumatol. 2012;31(3):435–40. https://doi.org/10.1007/s10067-011-1857-4.CrossRefPubMed

94.

Aboelenein HR, Hamza MT, Marzouk H, Youness RA, Rahmoon M, Salah S, Abdelaziz AI. Reduction of CD19 autoimmunity marker on B cells of paediatric SLE patients through repressing PU.1/TNF-α/BAFF axis pathway by miR-155. Growth Factors. 2017;35(2–3):49–60. https://doi.org/10.1080/08977194.2017.1345900.

95.

Wang Z, Heid B, Dai R, Ahmed SA. Similar dysregulation of lupus-associated miRNAs in peripheral blood mononuclear cells and splenic lymphocytes in MRL/lpr mice. Lupus Sci Med. 2018;5(1): e000290. https://doi.org/10.1136/lupus-2018-000290.CrossRefPubMedPubMedCentral

96.

Dai R, Zhang Y, Khan D, Heid B, Caudell D, Crasta O, Ahmed SA. Identification of a common lupus disease-associated microRNA expression pattern in three different murine models of lupus. PLoS ONE. 2010;5(12): e14302. https://doi.org/10.1371/journal.pone.0014302.CrossRefPubMedPubMedCentral

97.

Mohammed SR, Shaker OG, Mohammed AA, Fouad NA, Hussein HA, Ahmed NA, Ahmed OM, Ali DY, Mohamed MM, Ibrahim AA. Impact of miR-155 (rs767649 A>T) and miR-146a (rs57095329 A>G) polymorphisms in System Lupus Erythematosus susceptibility in an Egyptian cohort. Eur Rev Med Pharmacol Sci. 2021;25(3):1425–35.PubMed

98.

Weidenbusch M, Bai Y, Eder J, Anders HJ. Lupus Nephritis Trials Network. Refractory lupus nephritis: a survey. Lupus. 2019;28(4):455–64. https://doi.org/10.1177/0961203319828516.CrossRefPubMed

99.

Khoshmirsafa M, Kianmehr N, Falak R, Mowla SJ, Seif F, Mirzaei B, Valizadeh M, Shekarabi M. Elevated expression of miR-21 and miR-155 in peripheral blood mononuclear cells as potential biomarkers for lupus nephritis. Int J Rheum Dis. 2019;22(3):458–67. https://doi.org/10.1111/1756-185X.13410.CrossRefPubMed

100.

Liu F, Fan H, Ren D, Dong G, Hu E, Ji J, Hou Y. TLR9-induced miR-155 and Ets-1 decrease expression of CD1d on B cells in SLE. Eur J Immunol. 2015;45(7):1934–45. https://doi.org/10.1002/eji.201445286.CrossRefPubMed

101.

Hafez SS, Saad Wel S, Shedid NH. B-cell-attracting chemokine-1 (BCA-1/CXCL13) in systemic lupus erythematosus, its correlation to disease activity and renal involvement. Egypt J Immunol. 2014;21(2):23–32.PubMed

102.

Kong J, Li L, Lu Z, Song J, Yan J, Yang J, Gu Z, Da Z. MicroRNA-155 suppresses mesangial cell proliferation and TGF-β1 production via inhibiting CXCR5-ERK signaling pathway in Lupus Nephritis. Inflammation. 2019;42(1):255–63. https://doi.org/10.1007/s10753-018-0889-1.CrossRefPubMed

103.

Xin Q, Li J, Dang J, Bian X, Shan S, Yuan J, Qian Y, Liu Z, Liu G, Yuan Q, Liu N, Ma X, Gao F, Gong Y, Liu Q. miR-155 deficiency ameliorates autoimmune inflammation of Systemic Lupus Erythematosus by targeting S1pr1 in Faslpr/lpr mice. J Immunol. 2015;194(11):5437–45. https://doi.org/10.4049/jimmunol.1403028.CrossRefPubMed

104.

Rajasekhar M, Olsson AM, Steel KJ, Georgouli M, Ranasinghe U, Brender Read C, Frederiksen KS, Taams LS. MicroRNA-155 contributes to enhanced resistance to apoptosis in monocytes from patients with rheumatoid arthritis. J Autoimmun. 2017;79:53–62. https://doi.org/10.1016/j.jaut.2017.01.002.CrossRefPubMedPubMedCentral

105.

Wang Y, Feng T, Duan S, Shi Y, Li S, Zhang X, Zhang L. miR-155 promotes fibroblast-like synoviocyte proliferation and inflammatory cytokine secretion in rheumatoid arthritis by targeting FOXO3a. Exp Ther Med. 2020;19(2):1288–96. https://doi.org/10.3892/etm.2019.8330.CrossRefPubMed

106.

Abdul-Maksoud RS, Sediq AM, Kattaia A, Elsayed W, Ezzeldin N, Abdel Galil SM, Ibrahem RA. Serum miR-210 and miR-155 expression levels as novel biomarkers for rheumatoid arthritis diagnosis. Br J Biomed Sci. 2017;74(4):209–13. https://doi.org/10.1080/09674845.2017.1343545.CrossRefPubMed

107.

Mookherjee N, El-Gabalawy HS. High degree of correlation between whole blood and PBMC expression levels of miR-155 and miR-146a in healthy controls and rheumatoid arthritis patients. J Immunol Methods. 2013;400–401:106–10. https://doi.org/10.1016/j.jim.2013.10.001.CrossRefPubMed

108.

Long L, Yu P, Liu Y, Wang S, Li R, Shi J, Zhang X, Li Y, Sun X, Zhou B, Cui L, Li Z. Upregulated microRNA-155 expression in peripheral blood mononuclear cells and fibroblast-like synoviocytes in rheumatoid arthritis. Clin Dev Immunol. 2013. https://doi.org/10.1155/2013/296139.CrossRefPubMedPubMedCentral

109.

Li X, Tian F, Wang F. Rheumatoid arthritis-associated microRNA-155 targets SOCS1 and upregulates TNF-α and IL-1β in PBMCs. Int J Mol Sci. 2013;14(12):23910–21. https://doi.org/10.3390/ijms141223910.CrossRefPubMedPubMedCentral

110.

Murata K, Yoshitomi H, Tanida S, Ishikawa M, Nishitani K, Ito H, Nakamura T. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther. 2010;12(3):R86. https://doi.org/10.1186/ar3013.CrossRefPubMedPubMedCentral

111.

Kolarz B, Ciesla M, Dryglewska M, Rosenthal AK, Majdan M. Hypermethylation of the miR-155 gene in the whole blood and decreased plasma level of miR-155 in rheumatoid arthritis. PLoS ONE. 2020;15(6): e0233897. https://doi.org/10.1371/journal.pone.0233897.CrossRefPubMedPubMedCentral

112.

Mortazavi-Jahromi SS, Aslani M, Omidian S, Ahmadzadeh A, Rezaieyazdi Z, Mirshafiey A. Immunopharmacological effect of β-d-mannuronic acid (M2000), as a new immunosuppressive drug, on gene expression of miR-155 and its target molecules (SOCS1, SHIP1) in a clinical trial on rheumatoid arthritis patients. Drug Dev Res. 2020;81(3):295–304. https://doi.org/10.1002/ddr.21619.CrossRefPubMed

113.

Migita K, Iwanaga N, Izumi Y, Kawahara C, Kumagai K, Nakamura T, Koga T, Kawakami A. TNF-α-induced miR-155 regulates IL-6 signaling in rheumatoid synovial fibroblasts. BMC Res Notes. 2017;10(1):403. https://doi.org/10.1186/s13104-017-2715-5.CrossRefPubMedPubMedCentral

114.

Shaker OG, Abdelaleem OO, Fouad NA, Ali AMEA, Ahmed TI, Ibrahem EG, Abdelghaffar NK. Association between miR-155, its polymorphism and ischemia-modified albumin in patients with rheumatoid arthritis. J Interferon Cytokine Res. 2019;39(7):428–37. https://doi.org/10.1089/jir.2019.0001.CrossRefPubMed

115.

Rezaeepoor M, Pourjafar M, Tahamoli-Roudsari A, Basiri Z, Hajilooi M, Solgi G. Altered expression of microRNAs may predict therapeutic response in rheumatoid arthritis patients. Int Immunopharmaco. 2020;83: 106404. https://doi.org/10.1016/j.intimp.2020.106404.CrossRef

116.

Zhu Y, Yu HW, Pan YZ, Yang J, Zhou Q, Zhang M, Jiang L, Zhao C. [Effect of moxibustion at "Zusanli"(ST36) and "Shenshu"(BL23) on miR-155-mediated TLR4/NF-κB signaling involving amelioration of synovitis in rheumatoid arthritis rats]. Zhen Ci Yan Jiu. 2021;46(3):194–200. Chinese. https://doi.org/10.13702/j.1000-0607.200377.

117.

Ahmed Ali M, Gamil Shaker O, Mohamed Eid H, Elsayed Mahmoud E, Mahmoud Ezzat E, Nady GS. Relationship between miR-155 and miR-146a polymorphisms and susceptibility to multiple sclerosis in an Egyptian cohort. Biomed Rep. 2020;12(5):276–84. https://doi.org/10.3892/br.2020.1286.CrossRefPubMedPubMedCentral

118.

Mameli G, Arru G, Caggiu E, Niegowska M, Leoni S, Madeddu G, Babudieri S, Sechi GP, Sechi LA. Natalizumab therapy modulates miR-155, miR-26a and proinflammatory cytokine expression in MS patients. PLoS ONE. 2016;11(6): e0157153. https://doi.org/10.1371/journal.pone.0157153.CrossRefPubMedPubMedCentral

119.

Ksiazek-Winiarek D, Szpakowski P, Turniak M, Szemraj J, Glabinski A. IL-17 Exerts anti-apoptotic effect via miR-155-5p downregulation in experimental autoimmune encephalomyelitis. J Mol Neurosci. 2017;63(3–4):320–32. https://doi.org/10.1007/s12031-017-0981-2.CrossRefPubMedPubMedCentral

120.

Baulina N, Kulakova O, Kiselev I, Osmak G, Popova E, Boyko A, Favorova O. Immune-related miRNA expression patterns in peripheral blood mononuclear cells differ in multiple sclerosis relapse and remission. J Neuroimmunol. 2018;317:67–76. https://doi.org/10.1016/j.jneuroim.2018.01.005.CrossRefPubMed

121.

Luo D, Wang J, Zhang X, Rang X, Xu C, Fu J. Identification and functional analysis of specific MS risk miRNAs and their target genes. Mult Scler Relat Disord. 2020;41: 102044. https://doi.org/10.1016/j.msard.2020.102044.CrossRefPubMed

122.

Niwald M, Migdalska-Sęk M, Brzeziańska-Lasota E, Miller E. Evaluation of selected MicroRNAs expression in remission phase of multiple sclerosis and their potential link to cognition, depression, and disability. J Mol Neurosci. 2017;63(3–4):275–82. https://doi.org/10.1007/s12031-017-0977-y.CrossRefPubMed

123.

Amoruso A, Blonda M, Gironi M, Grasso R, Di Francescantonio V, Scaroni F, Furlan R, Verderio C, Avolio C. Immune and central nervous system-related miRNAs expression profiling in monocytes of multiple sclerosis patients. Sci Rep. 2020;10(1):6125. https://doi.org/10.1038/s41598-020-63282-3.CrossRefPubMedPubMedCentral

124.

Murugaiyan G, Beynon V, Mittal A, Joller N, Weiner HL. Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J Immunol. 2011;187(5):2213–21. https://doi.org/10.4049/jimmunol.1003952.CrossRefPubMed

125.

Venkatesha SH, Dudics S, Song Y, Mahurkar A, Moudgil KD. The miRNA expression profile of experimental autoimmune encephalomyelitis reveals novel potential disease biomarkers. Int J Mol Sci. 2018;19(12):3990. https://doi.org/10.3390/ijms19123990.CrossRefPubMedCentral

126.

Singh J, Deshpande M, Suhail H, Rattan R, Giri S. Targeted stage-specific inflammatory microRNA profiling in urine during disease progression in experimental autoimmune encephalomyelitis: markers of disease progression and drug response. J Neuroimmune Pharmacol. 2016;11(1):84–97. https://doi.org/10.1007/s11481-015-9630-0.CrossRefPubMed

127.

Zha Z, Gao YF, Ji J, Sun YQ, Li JL, Qi F, Zhang N, Jin LY, Xue B, Yang T, Fan YP, Zhao H, Wang L. Bu Shen, Yi Sui Capsule alleviates neuroinflammation and demyelination by promoting microglia toward m2 polarization, which correlates with changes in miR-124 and miR-155 in experimental autoimmune encephalomyelitis. Oxid Med Cell Longev. 2021;2021:5521503. https://doi.org/10.1155/2021/5521503.CrossRefPubMedPubMedCentral

128.

Zhao P, Chen X, Han X, Wang Y, Shi Y, Ji J, Lei Y, Liu Y, Kong Q, Mu L, Wang J, Zhao W, Wang G, Liu X, Zhang T, Zhang Y, Sun B, Liu Y, Li H. Involvement of microRNA-155 in the mechanism of electroacupuncture treatment effects on experimental autoimmune encephalomyelitis. Int Immunopharmacol. 2021;97: 107811. https://doi.org/10.1016/j.intimp.2021.107811.CrossRefPubMed

129.

Liu Y, Zhu F, Li H, Fan H, Wu H, Dong Y, Chu S, Tan C, Wang Q, He H, Gao F, Leng X, Zhou Q, Zhu X. MiR-155 contributes to intestinal barrier dysfunction in DSS-induced mice colitis via targeting HIF-1α/TFF-3 axis. Aging (Albany NY). 2020;12(14):14966–14977. https://doi.org/10.18632/aging.103555.

130.

Li N, Ouyang Y, Xu X, Yuan Z, Liu C, Zhu Z. MiR-155 promotes colitis-associated intestinal fibrosis by targeting HBP1/Wnt/β-catenin signalling pathway. J Cell Mol Med. 2021;25(10):4765–75. https://doi.org/10.1111/jcmm.16445.CrossRefPubMedPubMedCentral

131.

Schönauen K, Le N, von Arnim U, Schulz C, Malfertheiner P, Link A. Circulating and fecal microRNAs as biomarkers for inflammatory Bowel diseases. Inflamm Bowel Dis. 2018;24(7):1547–57. https://doi.org/10.1093/ibd/izy046.CrossRefPubMed

132.

Min M, Peng L, Yang Y, Guo M, Wang W, Sun G. MicroRNA-155 is involved in the pathogenesis of ulcerative colitis by targeting FOXO3a. Inflamm Bowel Dis. 2014;20(4):652–9. https://doi.org/10.1097/MIB.0000000000000009.CrossRefPubMed

133.

Butin-Israeli V, Bui TM, Wiesolek HL, Mascarenhas L, Lee JJ, Mehl LC, Knutson KR, Adam SA, Goldman RD, Beyder A, Wiesmuller L, Hanauer SB, Sumagin R. Neutrophil-induced genomic instability impedes resolution of inflammation and wound healing. J Clin Invest. 2019;129(2):712–26. https://doi.org/10.1172/JCI122085.CrossRefPubMedPubMedCentral

134.

Chao G, Li X, Ji Y, Zhu Y, Li N, Zhang N, Feng Z, Niu M. MiR-155 controls follicular Treg cell-mediated humoral autoimmune intestinal injury by inhibiting CTLA-4 expression. Int Immunopharmacol. 2019;71:267–76. https://doi.org/10.1016/j.intimp.2019.03.009.CrossRefPubMed

135.

Zeng J, Zhang D, Wan X, Bai Y, Yuan C, Wang T, Yuan D, Zhang C, Liu C. Chlorogenic acid suppresses miR-155 and ameliorates ulcerative colitis through the NF-κB/NLRP3 inflammasome pathway. Mol Nutr Food Res. 2020. https://doi.org/10.1002/mnfr.202000452.CrossRefPubMed

136.

Lu ZJ, Wu JJ, Jiang WL, Xiao JH, Tao KZ, Ma L, Zheng P, Wan R, Wang XP. MicroRNA-155 promotes the pathogenesis of experimental colitis by repressing SHIP-1 expression. World J Gastroenterol. 2017;23(6):976–85. https://doi.org/10.3748/wjg.v23.i6.976.CrossRefPubMedPubMedCentral

137.

Adamowicz M, Milkiewicz P, Kempinska-Podhorodecka A. 5-aminosalicylic acid inhibits the expression of oncomiRs and pro-inflammatory microRNAs: an in vitro study. J Physiol Pharmacol. 2021 https://doi.org/10.26402/jpp.2021.4.04.

138.

Din AU, Hassan A, Zhu Y, Zhang K, Wang Y, Li T, Wang Y, Wang G. Inhibitory effect of Bifidobacterium bifidum ATCC 29521 on colitis and its mechanism. J Nutr Biochem. 2020;79: 108353. https://doi.org/10.1016/j.jnutbio.2020.108353.CrossRefPubMed

139.

Rodríguez-Nogales A, Algieri F, Garrido-Mesa J, Vezza T, Utrilla MP, Chueca N, Fernández-Caballero JA, García F, Rodríguez-Cabezas ME, Gálvez J. The administration of Escherichia coli Nissle 1917 ameliorates development of DSS-induced colitis in mice. Front Pharmacol. 2018;9:468. https://doi.org/10.3389/fphar.2018.00468.CrossRefPubMedPubMedCentral

140.

Rodríguez-Nogales A, Algieri F, Garrido-Mesa J, Vezza T, Utrilla MP, Chueca N, Garcia F, Olivares M, Rodríguez-Cabezas ME, Gálvez J. Differential intestinal anti-inflammatory effects of Lactobacillus fermentum and Lactobacillus salivarius in DSS mouse colitis: impact on microRNAs expression and microbiota composition. Mol Nutr Food Res. 2017. https://doi.org/10.1002/mnfr.201700144.CrossRefPubMed

141.

Mostahfezian M, Azhir Z, Dehghanian F, Hojati Z. Expression pattern of microRNAs, miR-21, miR-155 and miR-338 in patients with Type 1 Diabetes. Arch Med Res. 2019;50(3):79–85. https://doi.org/10.1016/j.arcmed.2019.07.002.CrossRefPubMed

142.

Assmann TS, Recamonde-Mendoza M, Puñales M, Tschiedel B, Canani LH, Crispim D. MicroRNA expression profile in plasma from type 1 diabetic patients: Case-control study and bioinformatic analysis. Diabetes Res Clin Pract. 2018;141:35–46. https://doi.org/10.1016/j.diabres.2018.03.044.CrossRefPubMed

143.

Guay C, Kruit JK, Rome S, Menoud V, Mulder NL, Jurdzinski A, Mancarella F, Sebastiani G, Donda A, Gonzalez BJ, Jandus C, Bouzakri K, Pinget M, Boitard C, Romero P, Dotta F, Regazzi R. Lymphocyte-derived exosomal MicroRNAs promote pancreatic β cell death and may contribute to Type 1 Diabetes development. Cell Metab. 2019;29(2):348-361.e6. https://doi.org/10.1016/j.cmet.2018.09.011.CrossRefPubMed

144.

Assmann TS, Duarte GCK, Brondani LA, de Freitas PHO, Martins ÉM, Canani LH, Crispim D. Polymorphisms in genes encoding miR-155 and miR-146a are associated with protection to type 1 diabetes mellitus. Acta Diabetol. 2017;54(5):433–41. https://doi.org/10.1007/s00592-016-0961-y.CrossRefPubMed

145.

Zhu F, Liu J, Wang G, Fang L, Zhang P, Tan B. Xinfeng Capsule reduces hypercoagulative state in patients with Sjogren’s syndrome by inhibiting miR-155/SOCS1/NF-κB signaling pathway. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2016;32(10):1366–71.PubMed

146.

Yan Q, Chen J, Li W, Bao C, Fu Q. Targeting miR-155 to treat experimental scleroderma. Sci Rep. 2016;6:20314. https://doi.org/10.1038/srep20314.CrossRefPubMedPubMedCentral

147.

Artlett CM, Sassi-Gaha S, Hope JL, Feghali-Bostwick CA, Katsikis PD. Mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis. Arthritis Res Ther. 2017;19(1):144. https://doi.org/10.1186/s13075-017-1331-z.CrossRefPubMedPubMedCentral

148.

Hoang DH, Zhao D, Branciamore S, Maestrini D, Rodriguez IR, Kuo YH, Rockne R, Khaled SK, Zhang B, Nguyen LXT, Marcucci G. MicroRNA networks in FLT3-ITD acute myeloid leukemia. Proc Natl Acad Sci U S A. 2022;119(16): e2112482119. https://doi.org/10.1073/pnas.2112482119.CrossRefPubMedPubMedCentral

149.

Mann M, Mehta A, Zhao JL, Lee K, Marinov GK, Garcia-Flores Y, Lu LF, Rudensky AY, Baltimore D. An NF-κB-microRNA regulatory network tunes macrophage inflammatory responses. Nat Commun. 2017;8(1):851. https://doi.org/10.1038/s41467-017-00972-z.CrossRefPubMedPubMedCentral

Titel: Role of miR-155 in inflammatory autoimmune diseases: a comprehensive review
verfasst von: Wang-Dong Xu
Si-Yu Feng
An-Fang Huang
Publikationsdatum: 29.10.2022
Verlag: Springer International Publishing
Erschienen in: Inflammation Research / Ausgabe 12/2022
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-022-01643-6

USP7 accelerates FMR1-mediated ferroptosis by facilitating TBK1 ubiquitination and DNMT1 deubiquitination after renal ischemia–reperfusion injury

Original Article

C/EBPβ enhances immunosuppression activity of myeloid-derived suppressor cells by a P300-mediated acetylation modification

Original Research

GITRL impairs the immunosuppressive function of MDSCs via PTEN-mediated signaling pathway in experimental Sjögren syndrome

Original Research

The macrophage senescence hypothesis: the role of poor heat shock response in pulmonary inflammation and endothelial dysfunction following chronic exposure to air pollution

Review

Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review

COVID-19
Review

The inflammasomes: crosstalk between innate immunity and hematology

Review

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

ctDNA erkennt minimale Resterkrankung beim Melanom

25.04.2025
Tumormarker
Nachrichten

Die Diagnose einer minimalen Resterkrankung mithilfe zirkulierender Tumor-DNA könnte (ctDNA) auch das Management von Patientinnen und Patienten mit Melanomen im Stadium III bereichern, wie Ergebnisse einer Studie nahelegen – auch wenn die Methode noch nicht perfekt funktioniert.

Lipidtherapie im Praxisalltag: Noch viel Spielraum für Verbesserung

25.04.2025
DGK-Jahrestagung 2025
Kongressbericht

Wie steht es um die Behandlung von Dyslipidämien bei Risikopatienten mit atherosklerotischer Gefäßerkrankung in Deutschland? Eine Bestandsaufnahme dazu liefert das bei der DGK-Tagung 2025 vorgestellte Forschungsprojekt LipidSnapshot.

Lohnt sich die Karotis-Revaskularisation?

25.04.2025
Karotisstenose
Nachrichten

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Höhere Dosis von Dexamethason senkt Überlebenschancen

25.04.2025
Zerebrale Metastasen
Nachrichten

Personen mit Hirnmetastasen, die perioperativ höhere kumulative Dosen von Dexamethason erhalten, haben eine schlechtere Prognose. Um die Ergebnisse zu verbessern, bedarf es strengerer Dosierungsschemata.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Role of miR-155 in inflammatory autoimmune diseases: a comprehensive review

Abstract

Purpose

Materials and methods

Conclusion

Weitere Artikel der Ausgabe 12/2022

USP7 accelerates FMR1-mediated ferroptosis by facilitating TBK1 ubiquitination and DNMT1 deubiquitination after renal ischemia–reperfusion injury

C/EBPβ enhances immunosuppression activity of myeloid-derived suppressor cells by a P300-mediated acetylation modification

GITRL impairs the immunosuppressive function of MDSCs via PTEN-mediated signaling pathway in experimental Sjögren syndrome

The macrophage senescence hypothesis: the role of poor heat shock response in pulmonary inflammation and endothelial dysfunction following chronic exposure to air pollution

Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review

The inflammasomes: crosstalk between innate immunity and hematology

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Neu im Fachgebiet Innere Medizin

ctDNA erkennt minimale Resterkrankung beim Melanom

Lipidtherapie im Praxisalltag: Noch viel Spielraum für Verbesserung

Lohnt sich die Karotis-Revaskularisation?

Höhere Dosis von Dexamethason senkt Überlebenschancen

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

Update Innere Medizin

Springer Medizin

Abstract

Purpose

Materials and methods

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten